الفهرس | Only 14 pages are availabe for public view |
Abstract The intra-aortic balloon pump (IABP) is a myocardial assist device that was first introduced into clinical practice in 1968. Since its introduction into medicine, the IABP has become one of the most commonly used myocardial assist devices, with an annual estimate of 200 000 worldwide and 130 000 implanted devices in the United States in 2010. As the technology behind IABPs continues to evolve and the comfort level of practitioners placing these devices increases, it is imperative for clinicians to understand the principles of aortic counter pulsation, indications for using IABPs and management of any potential complications (Kapelios, 2014). IABP therapy is frequently referred to as ”counter pulsation” because the balloon inflation occurs during diastole and balloon deflation occurs during systole. IABP counter pulsation increases cardiac output CO. Patients frequently experience relief from ischemic chest pain or angina equivalent within minutes of starting IABP therapy (Rogers, 2009). The prophylactic use of preoperative IABC in patients with cardiogenic shock and other risk factors undergoing surgical coronary revascularization has been a matter of debate, with some studies showing a benefit, others showing no benefit, and still others showing a harm with its use (Joskowiak et al., 2011). |